Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
GIST
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - GIST
    Surgery Following Imatinib Treatment Appears to Improve Progression-Free Survival in Patients With GIST: Presented at ASCO - (DGDispatch)
    Patients With Gastrointestinal Stromal Tumour Have Increased Risk of Second, Non-GIST Malignancies: Presented at ASCO - (DGDispatch)
    NICE Recommends Sunitinib Malate as Second-Line Therapy for Advanced GIST - (DGNews)
    Imatinib Approved in EU to Reduce Relapse Risk After GIST Surgery - (DGNews)
    Sorafenib Shows Activity as Fourth-Line Therapy for Patients With GIST Tumours: Presented at ASCO-GI - (DGDispatch)

    News archive

     Recent webcasts/CME - GIST

    Webcasts/CME archive

     Recent cases - GIST
      The Clinicopathologic Observation, C-KIT Gene Mutation and Clonal Status of Gastrointestinal Stromal Tumor in the Sacrum
      Gastrointestinal Stromal Tumors with Pseudocystic Change Mimicking a Pancreatic Tumor: Two Case Reports
      Synchronous Colorectal Adenocarcinoma and Gastrointestinal Stromal Tumor in Meckel's Diverticulum; An Unusual Association
      Dramatic Response of a Gastrointestinal Stromal Tumor to Neadjuvant Imatinib Therapy
      Pancreatic Insulinoma Co-Existing with Gastric GIST in the Absence of Neurofibromatosis-1

      Cases archive
        




      my personal edition > gist > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Survival Similar With Partial and Total Resection of Gastrointestinal Stromal Tumors: Presented at SSO

      By Crystal Phend

      SAN DIEGO, C.A. -- March 27, 2006 -- Long-term survival after partial resection of gastrointestinal stromal tumors (GIST) appears to approach that of total resection, according to a study presented here at the annual meeting of the Society of Surgical Oncology (SSO).

      The researchers in this study also found that adjuvant imatinib therapy may provide a synergistic survival benefit.

      "Even taking part of the tumor, not the whole thing, you get an improvement in survival," said lead author Eduardo A. Perez, MD, general surgery resident, University of Miami Miller School of Medicine, Miami, Florida, United States, in his presentation March 24th.

      The researchers analyzed 11 years of data from the Surveillance, Epidemiology, and End Results (SEER) database. Of the 1873 tumors identified, 82% were GIST; the rest were classified as smooth-muscle neoplasms.

      Median 5-year survival was significantly better for patients treated surgically compared to those who did not receive surgery. Patients who received radical resection had significantly worse survival outcomes than any other group, even those who did not get surgery.

      Total resection and partial resection had similar 11-year survival curves, Dr. Perez reported. Total resection was not associated with statistically improved survival compared to partial resection (51.6% versus 44.7%). Although this finding was shown in other studies, it remains controversial, he added.

      Median survival rates both overall and for individual treatment types except radical resection significantly improved after 2000. Overall 2-year survival increased from 59% to 72.9%.

      "Improved outcomes after 2000 indicate the potential benefit of newer therapies, including imatinib," Dr. Perez said.

      The only factors independently and significantly correlated with improved survival were treatment after the year 2000 and surgical treatment (versus no treatment).

      Patients with distant disease who underwent partial or total GIST resection had a significantly improved survival rate compared to those who did not have the surgery. Dr. Perez said this result may have been due to selection bias, but "these data support a palliative therapeutic role for resection of the primary malignancy in all patients with metastatic GIST," he said.


      [Presentation title: Surgery with Adjuvant Imatinib Therapy Provides a Synergistic Survival Benefit in the Treatment of Gastrointestinal Stromal Tumors. Poster 58]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send